SEC Company Response from NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — Dec 14, 2010
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: Dec. 14, 2010 · CIK: 0001389545 · Accession: 0001437749-10-004382
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-33678
Referenced dates: December 14, 2010
Letter
VIA EDGAR Securities and Exchange Commission NovaBay Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2009 Filed March 30, 2010 File No. 001-33678
Dear Mr. Rosenberg:
NovaBay Pharmaceuticals, Inc. (“NovaBay”) is electronically transmitting this letter to the Staff of the Securities and Exchange Commission in response to comments received from the Staff contained in the letter from the Staff, dated December 14, 2010, with respect to NovaBay’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, filed by NovaBay with the Securities and Exchange Commission on March 30, 2010.
This letter will confirm that NovaBay intends to file its written response to the Staff’s comment letter no later than Friday, January 7, 2011. Please contact me at (510) 899-8809, or Brett White of Cooley LLP at (650) 843-5191, with any questions or comments.
Sincerely,
NovaBay Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
novabay_corr-121410.htm
VIA EDGAR
December 14, 2010
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-3628
Re:
NovaBay Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2009
Filed March 30, 2010
File No. 001-33678
Dear Mr. Rosenberg:
NovaBay Pharmaceuticals, Inc. (“NovaBay”) is electronically transmitting this letter to the Staff of the Securities and Exchange Commission in response to comments received from the Staff contained in the letter from the Staff, dated December 14, 2010, with respect to NovaBay’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, filed by NovaBay with the Securities and Exchange Commission on March 30, 2010.
This letter will confirm that NovaBay intends to file its written response to the Staff’s comment letter no later than Friday, January 7, 2011. Please contact me at (510) 899-8809, or Brett White of Cooley LLP at (650) 843-5191, with any questions or comments.
Sincerely,
NovaBay Pharmaceuticals, Inc.
By:
/s/ Thomas J. Paulson
Thomas J. Paulson
Chief Financial Officer
cc:
Ron Najafi, President and Chief Executive Officer
Brett White, Cooley LLP
NOVABAY PHARMACEUTICALS, INC.
5980 Horton Street, Suite 550, Emeryville, CA 94608 - Phone: 510-899-8800
www.novabaypharma.com